Literature DB >> 7697948

Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography.

M Bergström1, A Nordberg, E Lunell, G Antoni, B Långström.   

Abstract

The deposition of 11C-nicotine in the respiratory tract from a nicotine vapor inhaler was studied by means of positron emission tomography (PET) in an intrasubject comparison of six healthy smokers using two modes of inhalation: one with shallow, frequent inhalations ("buccal mode") and one with deep inhalations ("pulmonary mode"). An average of 15% of the radioactivity was released from the vapor inhaler after 5 minutes of inhalation. Approximately 45% of the dose released was found in the oral cavity. A significant amount of radioactivity, 10%, was observed in the esophagus, suggesting transfer of a major fraction of the dose to the stomach. Only a minor fraction, 5%, was found in the lungs, followed by 2% in the bronchi and 1% in the trachea. The deposition in the oral cavity closely followed a linear pattern during the 5 minutes of inhalation and was followed by a rapid elimination from the oral cavity, with an average half-life of 18 minutes. Only 8% of the dose released remained in the oral cavity 45 minutes after the end of inhalation. On the other hand, the dose fraction of about 14% distributed into the body tissue compartment at the end of inhalation had risen to 60% at that late time point. No statistically or clinically important differences were observed between the buccal and the pulmonary mode of inhalation in either deposition pattern or elimination rates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697948     DOI: 10.1016/0009-9236(95)90156-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 2.  Tobacco Use Cessation and Prevention - A Review.

Authors:  Sabiha Shaheen Shaik; Dolar Doshi; Srikanth Reddy Bandari; Padma Reddy Madupu; Suhas Kulkarni
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 3.  A review of smoking cessation interventions.

Authors:  Ashish Maseeh; Gagandeep Kwatra
Journal:  MedGenMed       Date:  2005-06-07

4.  Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents.

Authors:  G Ferris Wayne; G N Connolly; J E Henningfield
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

5.  Development and optimization of a novel automated loop method for production of [11C]nicotine.

Authors:  Arijit Ghosh; Karen Woolum; Michael V Knopp; Krishan Kumar
Journal:  Appl Radiat Isot       Date:  2018-05-30       Impact factor: 1.513

Review 6.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

7.  Chronic intermittent nicotine delivery via lung alveolar region-targeted aerosol technology produces circadian pharmacokinetics in rats resembling human smokers.

Authors:  Xuesi M Shao; Siyu Liu; Eon S Lee; David Fung; Hua Pei; Jing Liang; Ross Mudgway; Jingxi Zhang; Jack L Feldman; Yifang Zhu; Stan Louie; Xinmin S Xie
Journal:  J Appl Physiol (1985)       Date:  2018-09-20

8.  Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms.

Authors:  E Lunell; L Molander; S J Leischow; K O Fagerström
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Treating tobacco dependence in a medical setting.

Authors:  Richard D Hurt; Jon O Ebbert; J Taylor Hays; David D McFadden
Journal:  CA Cancer J Clin       Date:  2009-08-25       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.